Isoflavone Formulation with Whey Protein Carrier
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for metabolic abnormalities such as insulin resistance, impaired glucose tolerance, hypertension, obesity, and metabolic syndrome are inadequate in effectively managing these conditions without causing increased estrogenic activity.
Innovation Solution
Formulating isoflavones with soluble carrier proteins, specifically mammalian whey protein, to create a composition called lactoflavone, which reduces plasma lipid levels and enhances insulin sensitivity without increased estrogenic activity, thereby modulating lipid metabolism and potentially treating metabolic dysfunction and cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If isoflavones are used to treat metabolic abnormalities, then lipid metabolism is modulated and insulin sensitivity is improved, but estrogenic activity is increased which may cause unwanted side effects
Solution Approach 1:
The patent uses carrier proteins (such as albumin, globulin, or immunoglobulin) as intermediary substances to bind with isoflavones. This binding complex allows the isoflavones to be transported in the bloodstream without exerting estrogenic effects, while still maintaining their ability to modulate lipid metabolism and improve insulin sensitivity when delivered to target tissues.
Solution Approach 2:
The patent extracts and isolates specific isoflavone compounds from soybean extracts and combines them with carrier proteins. This process separates the beneficial metabolic effects of isoflavones from their estrogenic activity, allowing selective delivery of the metabolic benefits through protein-bound isoflavone complexes to tissues needing lipid metabolism modulation.
2Reliability
If soy protein is used to improve metabolic parameters, then insulin resistance and glucose tolerance are improved, but the formulation complexity increases
Solution Approach 1:
The patent employs carrier proteins that serve multiple functions: they bind isoflavones to prevent estrogenic activity, provide a controlled release mechanism for metabolic benefits, and can be derived from common food sources. This multi-functionality simplifies the overall formulation approach while maintaining therapeutic effectiveness.
Solution Approach 2:
The patent modifies the physical and chemical parameters of isoflavone delivery by changing their binding state (free vs. protein-bound), molecular size, and release kinetics. These parameter changes enable the isoflavones to be delivered in a form that avoids estrogenic activity while maintaining metabolic benefits, without requiring complex multi-component formulations.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Abstract This invention relates to the formulations of isoflavones with soluble carrier proteins, for example whey proteins. The formulations display increased lipid modulating activity without increased estrogenic activity, relative to isoflavone alone and may be useful, for example in therapeutic applications, such as the treatment of metabolic dysfunction, cancer and skin conditions.